A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This clinical trial is a Phase 1-2, open-label, multi-center, dose-escalation and expansion
study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of
daily oral administration of OP-1250.